Latest news with #RegeneronPharmaceuticals'
Yahoo
13 hours ago
- Business
- Yahoo
Consumer sentiment, Regeneron meeting, Apple WWDC: What to Watch
Market Domination Overtime hosts Julie Hyman and Josh Lipton preview the top market stories and headlines Wall Street will be paying attention to tomorrow, Friday, June 13, including June's preliminary consumer sentiment reading, Regeneron Pharmaceuticals' (REGN) annual shareholder meeting, and the closing day of Apple's (AAPL) 2025 Worldwide Developers Conference (WWDC). To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime here. Time now for to watch Friday, June 13th, starting off on the consumer monthly consumer sentiment data for June. It's coming out in the morning. Economist forecasting that number to rise compared to May's reading to 53.6 signaling that consumers are feeling slightly more optimistic about the economy, but while the rise suggests more confidence in the consumer, the number is still hovering at what we know is historically low levels. Taking a look at the healthcare sector, Regeneron holding its annual shareholder meeting tomorrow. It's been a rough year for the industry with Regeneron, no exceptions. Down nearly 30% so far this year. Investors will be looking out for any commentary on the company's recent agreement to acquire DNA testing company 23 and Me. And finally, Apple wrapping up its worldwide developers conference in California, the company announcing sweeping updates to each of its operating systems, including enhancements to its iPads and unveiling a new liquid glass redesign. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
13 hours ago
- Business
- Yahoo
Consumer sentiment, Regeneron meeting, Apple WWDC: What to Watch
Market Domination Overtime hosts Julie Hyman and Josh Lipton preview the top market stories and headlines Wall Street will be paying attention to tomorrow, Friday, June 13, including June's preliminary consumer sentiment reading, Regeneron Pharmaceuticals' (REGN) annual shareholder meeting, and the closing day of Apple's (AAPL) 2025 Worldwide Developers Conference (WWDC). To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime here. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
15 hours ago
- Business
- Yahoo
Consumer sentiment, Regeneron meeting, Apple WWDC: What to Watch
Market Domination Overtime hosts Julie Hyman and Josh Lipton preview the top market stories and headlines Wall Street will be paying attention to tomorrow, Friday, June 13, including June's preliminary consumer sentiment reading, Regeneron Pharmaceuticals' (REGN) annual shareholder meeting, and the closing day of Apple's (AAPL) 2025 Worldwide Developers Conference (WWDC). To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime here.
Yahoo
08-05-2025
- Business
- Yahoo
2 Unstoppable Dividend Stocks to Buy and Hold Forever
Amgen is an innovative leader in an industry where its products will always be in high demand. Microsoft is navigating the current situation well and boasts lucrative growth opportunities. Both companies have increased their payouts at a good clip over the past decade. 10 stocks we like better than Amgen › Some research has shown that dividend-paying stocks significantly outperformed their non-dividend-paying peers over the past few decades, and that the lion's share of market returns can be attributed to reinvested dividends and compounding. Those are excellent arguments for investing in dividend stocks and holding on to them for a long time. However, not all dividend-paying companies are equally attractive. Which ones should you consider? Two excellent options right now are Amgen (NASDAQ: AMGN) and Microsoft (NASDAQ: MSFT). Here's why these two income stocks are worth sticking with for good. It's never a bad idea to turn to leading drugmakers like Amgen when looking for forever stocks. The business of developing and marketing innovative therapies for serious, sometimes life-threatening diseases will never go out of style until we find all-purpose cures for all conditions. While individual drugmakers could fail, Amgen's business looks strong enough to avoid that fate for a long time. It boasts an extensive lineup of medicines, with over 10 that each generated upwards of $1 billion in sales in 2024. In the first quarter, revenue increased by a strong 9% year over year to $8.1 billion. Amgen's lineup is diversified across several therapeutic areas, including oncology, immunology, rare diseases, and respiratory diseases. Key growth drivers (not an exhaustive list) include Tezspire, an asthma medication; Repatha, which treats high cholesterol; and blood-cancer medicine Blincyto. Like every drugmaker, Amgen will, at some point, face patent cliffs that will erode sales of important products. The way to get around this issue is to develop newer medicines. Looking at the company's pipeline, it seems more than capable of doing so. It boasts a few dozen programs that should lead to label expansions and brand-new approvals. The company has been working on a promising weight management candidate, MariTide. Though this product somewhat disappointed in phase 2 studies, it's still in the running to reach the market and generate decent sales, considering how rapidly the anti-obesity space is growing. Besides, Amgen is developing another weight loss candidate that's still in phase 1 studies. Weight loss isn't the only area the biotech is going after; it has exciting products across others. In the biosimilar realm, it recently launched Pavblu, a competitor to Regeneron Pharmaceuticals' blockbuster, Eylea, which treats an eye condition called wet age-related macular degeneration. Amgen should be able to overcome future losses of patent exclusivity for key products, even if it goes through periods of declining sales as a result. The stock should perform well in the long run and continue rewarding shareholders with regular dividends. The company has increased its payouts by 201% in the past decade so it currently offers a forward yield of 3.4% -- while the average for the S&P 500 is 1.3%. Amgen might not be as exciting as certain tech companies, but the stock looks like a strong buy-and-forget pick. Microsoft's shares struggled for much of the year. The threat of tariffs and the fear that they could lead to an inflationary environment or a recession (or both) weighed on many tech giants, including Microsoft. However, the company more or less put those fears to bed (for now) with its latest quarterly update, for the third quarter of its fiscal year 2025, ending March 31. Revenue jumped by 13% year over year to $70.1 billion. The tech leader can thank its cloud computing arm, Microsoft Azure, for that performance; the segment's revenue jumped by 33% (or 35% in constant currency) compared to the year-ago period. And there's more where that came from. In its fourth quarter, Microsoft expects Azure revenue to increase 34% to 35% in constant currency. So, despite economic uncertainty, the company is doing fine. The important lesson here isn't that its quarter was strong. It's that even during challenging times, Microsoft can perform relatively well. That's why the stock has thrived for decades, making longtime shareholders much wealthier. Microsoft's ability to navigate tough periods is one factor that makes it an attractive forever stock. Here are two more. First, the company has a strong moat from its brand name and switching costs within its cloud and software productivity businesses. Second, it has attractive long-term growth opportunities; cloud computing and artificial intelligence (AI) are the most exciting of the bunch. That means that even with a market capitalization above $3 trillion, Microsoft still has a bright future, and the company's dividend looks safe. It might only have a forward yield of 0.8%, but the rock-solid underlying business, ability to generate plenty of cash, and consistent dividend growth record (it's increased its payouts by 168% over the past 10 years) more than make up for the low yield. Microsoft is a top stock to hold on to for growth and income investors alike. Before you buy stock in Amgen, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Amgen wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $623,103!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $717,471!* Now, it's worth noting Stock Advisor's total average return is 909% — a market-crushing outperformance compared to 162% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of May 5, 2025 Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Amgen, Microsoft, and Regeneron Pharmaceuticals. The Motley Fool recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy. 2 Unstoppable Dividend Stocks to Buy and Hold Forever was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Korea Herald
10-04-2025
- Business
- Korea Herald
Celltrion wins 3 biosimilar approvals in Australia, eyes Oceania growth
South Korea's pharmaceutical giant Celltrion said Thursday it has received regulatory approvals for three biosimilars in Australia over the past two weeks, a move expected to amplify its presence in the Oceania market. According to the biosimilar maker, the approvals from Australia's Therapeutic Goods Administration cover eye treatment Eydenzelt, its version of Regeneron Pharmaceuticals' Eylea, as well as two bone-related therapies Stoboclo and Osenvelt, referencing Amgen's Prolia and Xgeva, respectively. With the newest additions, Celltrion now has 11 products either approved or marketed in Australia. 'Australia's biosimilar-friendly environment continues to spur our growth momentum,' a company official said. 'We aim to complete the remaining commercialization steps swiftly to ensure stable supply in the market.' Eydenzelt, available in both vial and prefilled syringe forms, has been approved for the treatment of myopic choroidal neovascularization, or CNV, making it the first biosimilar in its category to gain approval in Australia. Its reference product, Eylea, generated $9.52 billion in global sales last year, underlining strong market potential, the company noted. Stoboclo and Osenvelt were approved for all indications held by their reference biologics in Australia. Stoboclo is indicated for postmenopausal osteoporosis, while Osenvelt is approved for preventing skeletal-related events in cancer patients with bone metastases and for treating giant cell tumors of bone. Their originator drugs Prolia and Xgeva recorded a combined $6.59 billion in global sales last year. The company said the approvals mark a key milestone in expanding its global reach, including in the Oceania region, with additional plans to broaden its pipeline in ophthalmology and bone-related therapies.
